Navigation Links
Biopure Announces 2008 First Quarter Financial Results
Date:2/21/2008

CAMBRIDGE, Mass., Feb. 21 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) today announced its financial results for the first fiscal quarter ended January 31, 2008. For the quarter, the company reported a net loss of $5.8 million, or $0.17 per common share, compared with a net loss of $6.9 million, or $0.53 per common share, for the corresponding period in 2007. Class A common shares outstanding on January 31, 2008 and 2007 were 34,971,087 and 15,543,025, respectively.

Revenues

Total revenues for the first fiscal quarter of 2008 were $573,000, including $419,000 from sales of the Company's veterinary product Oxyglobin(R), $58,000 from sales of Hemopure(R) in South Africa and $96,000 in research and development expense reimbursements from the U.S. government. Total revenues for the same period in fiscal 2007 were $594,000, including $444,000 from Oxyglobin sales, $16,000 from sales of Hemopure and $134,000 from government reimbursement. Payments from the government reimburse Biopure for trauma development expenses for Hemopure and vary with the amount of reimbursable activity for the government.

Oxyglobin revenues decreased during the first fiscal quarter of 2008 compared to 2007 because of a change in the arrangement between the Company and its European distributor. During the first quarter of fiscal 2007, the Company accounted for European sales on a consignment basis. Now the distributor buys product for its inventory upon shipment by the Company. The distributor did not purchase any inventory during the first fiscal quarter of 2008. This decrease was nearly offset by higher U.S. sales of Oxyglobin due to higher average selling prices. Hemopure sales increased during the first fiscal quarter of 2008 due
'/>"/>

SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Biopure Launches Updated Website
2. Biopure Announces Pricing of Equity Offering
3. Biopure Gives Update on Malaysia Joint Venture Discussions
4. PPD Announces Plan to Repurchase Shares of its Common Stock
5. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
6. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
7. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
8. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
9. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
10. Telik Announces Revised Date for Year-End Financial Release, Conference Call and Webcast
11. 3SBio Inc. Announces Change to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014 ... analyze and research medicinal plants and therapeutic derivatives ... industry, health professionals, and researchers about the challenges ... (Logo: http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014  RXi ... on discovering, developing and commercializing innovative therapies addressing ... announced that it received the Notice of Allowance ... on its unique self-delivering RNAi compounds (sd-rxRNA®), for ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental ... about dual arch impressions on its dental blog. ... blog entry serves up a list of tips to help ... by Dr. David Little as he crafts a porcelain crown ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... (Nasdaq: ARNA ) today announced it will report ... closes on Monday, May 11, 2009. That same afternoon, Jack ... Hoffman, Arena,s Vice President, Finance and Chief Financial Officer, will ... p.m. Pacific Time) to discuss the financial results for the ...
... On Thursday, May 7, 2009, at 8:30 a.m. Eastern/2:30 p.m. Central ... CTIC) management team will host a conference call to discuss the Company,s ... Conference Call Numbers, ... 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time, ...
... Biotech Inc. (TSX:ONC, NASDAQ: ONCY ) ("Oncolytics" or ... three-month period ended March 31, 2009. , "The first ... very positive results in several of our combination REOLYSIN(R) ... of Oncolytics. "We continue to report clinical benefit in ...
Cached Biology Technology:Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009 3Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7 2Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 2Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 3Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 4Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 5Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 6Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 7Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 8
(Date:4/22/2014)... Biotechnology scientists must be aware of the broad ... guidelines, according to a new paper from Rice University,s ... current issue of the journal Regenerative Medicine , ... Supreme Court ruling in the case Association for Molecular ... are unpatentable. The court case and rulings garnered discussion ...
(Date:4/22/2014)... Scientists at the University of Massachusetts Amherst and ... this week report that they have discovered a new ... of the Negro River in the Amazonia State of ... with Adlia Nogueira and Jos Antnio Alves-Gomes of INPA, ... of the journal Proceedings of the Natural Sciences ...
(Date:4/22/2014)... of nanotechnology researchers at the University of Kentucky has ... arrays using RNA. , The research, led by ... in Nanobiotechnology at the UK College of Pharmacy and ... "RNA as a Boiling-Resistant Anionic Polymer Material To Build ... Emil F. Khisamutdinov and Daniel L. Jasinski. , The ...
Breaking Biology News(10 mins):New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3New electric fish genus and species discovered in Brazil's Rio Negro 2RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2
... from the Department of Defense will allow North Carolina ... Institute of Research to further test the effectiveness of ... infections. The two-and-a-half-year project will show the efficacy ... and Dr. John Cavanagh against different types of animal ...
... McMaster University is establishing the first NVIDIA CUDA ... of only twelve worldwide, will teach electrical and ... processing resources available in graphics processing units (GPU) ... CUDA is a parallel computing architecture that enables ...
... antibacterial ingredient in some soaps, toothpastes, odor-fighting socks, and ... new treatment for a parasitic disease that affects almost ... the guiding light for future development of drugs for ... Chemistry . In the study, Rima McLeod and ...
Cached Biology News:NC State research grant will help military combat infections 2McMaster, NVIDIA establish first CUDA Teaching Centre in Canada 2
...
... maintenance, calibration, and validation (MCV) ... 96-well plate used for hands-free ... procedures using the Bio-Plex suspension ... is for use with Bio-Plex ...
...
... SureLINK HRP Conjugation Kits are based ... conjugates that are consistent and reproducible. ... to conjugate your protein or antibody, ... storage buffer. Activated HRP is ...
Biology Products: